Trials / Completed
CompletedNCT00846456
Safe Study of Dendritic Cell (DC) Based Therapy Targeting Tumor Stem Cells in Glioblastoma
Phase I/II Trial of Vaccine Therapy With Tumor Stem Cell Derived mRNA- Transfected Dendritic Cells in Patients Receiving Standard Therapy for Glioblastoma
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Oslo University Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The study induces an immune response towards the stem-cell like part of glioblastomas in combination with standard therapy. The aim is to define and characterize the feasibility, potential adverse effects of such therapy and measure time to progression and survival.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Dendritic cell vaccine with mRNA from tumor stem cells | Intradermal injection of transfected dendritic cells |
Timeline
- Start date
- 2009-01-01
- Primary completion
- 2013-02-01
- Completion
- 2013-02-01
- First posted
- 2009-02-18
- Last updated
- 2015-10-20
Source: ClinicalTrials.gov record NCT00846456. Inclusion in this directory is not an endorsement.